Please login to the form below

Not currently logged in
Email:
Password:

brentuximab vedotin

This page shows the latest brentuximab vedotin news and features for those working in and with pharma, biotech and healthcare.

AZ nabs US approval for new leukaemia drug Lumoxiti

AZ nabs US approval for new leukaemia drug Lumoxiti

Seattle Genetics/Takeda’s classical Hodgkin lymphoma therapy Adcetris (brentuximab vedotin) and Roche’s Kadcyla (trastuzumab emtansine) for breast cancer.

Latest news

More from news
Approximately 3 fully matching, plus 24 partially matching documents found.

Latest Intelligence

  • Interview: Trevor Smith, Takeda Interview: Trevor Smith, Takeda

    Even closer to market is Takeda's monoclonal antibody treatment for Hodgkin's Lymphoma, Adcetris (brentuximab vedotin), which was recommended for European approval in July and which Takeda expects to launch

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Wisepress

Wisepress is a medical bookseller promoting and selling books worldwide, both online and via the 200 European medical conferences that...

Latest intelligence

Three billboards on the road to multichannel
Chris Ross examines the trends driving multichannel communication in 2019...
How Medisafe is using AI to improve patient adherence
Dina Patel speaks to Omri Shor, Co-Founder and CEO of Medisafe, to find out how his medication management app is tackling the problem of poor adherence....
Cell and gene therapy
Tackling the manufacturing cost and complexity challenges...

Infographics